the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease
Recruiting
Observational Study
Fabry Disease
Cardiovascular Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 54 (estimated)
- Sponsor
- Caroline Michaela Kistorp · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The overall objective of this study is to investigate Fabry-related cardiomyopathy and the use of native T1-mapping, coronary microvascular function, cardiac inflammation, and cardiac injury in an effort to improve the ability to detect disease. The study aims to achieve this by:
1. Investigating the association between cardiac inflammation, fibrosis, and injury against the distribution and degre…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Patients with Fabry disease (1)
Inclusion Criteria:
* Male and female individuals with a genetically-verified diagnosis of Fabry disease
* ≥ 18 years of age
* Able to give informed consent
Exclusion Criteria:
* Any contraindication against a pharmacologically induced rest-stress PET/CT protocol …
Contacts